Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation—a pharmacological fMRI study
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Pharmacological functional MRI (phMRI) examines the impact of pharmacologically induced neurochemical changes on brain function at a system level. The current phMRI study directly compared effects of cholinergic stimulation on brain function between patients with Alzheimer's disease and mild cognitive impairment, a disease stage preceding the development of Alzheimer's disease. Brain function during recognition of (un)familiar information was examined for changes after exposure to galantamine, a cholinesterase inhibitor used for treating memory deficits in Alzheimer's disease. Alzheimer patients [n = 18; age 74.5 years +/- 8.2; Mini-Mental State Examination (MMSE) 22.5 +/- 2.4] and patients with mild cognitive impairment (n = 28; mean age 73.6 +/- 7.5; MMSE 27.0 +/- 1.2) were scanned during face recognition under three different conditions: at baseline, and after acute (single dose) and prolonged exposure (5 days) to galantamine. Functional data were analysed in an event-related fashion. In both groups, acute exposure produced strong increases in brain activation (Z > 3.1). Prolonged exposure produced less strong effects that mainly involved decreases in activation (Z > 3.1). In mild cognitive impairment, acute exposure increased activation in posterior cingulate, left inferior parietal, and anterior temporal lobe. Prolonged exposure decreased activation in similar posterior cingulate areas, and in bilateral prefrontal areas. Effects were stronger for positive ('familiar') than for negative ('unfamiliar') decisions, indicating that the effect was specific to memory retrieval. In Alzheimer patients, acute exposure increased activation bilaterally in hippocampal areas, whereas prolonged exposure decreased activation in these areas. Effects were more pronounced for negative than for positive decisions, suggesting a preferential effect on memory encoding. Unique profiles of signal reactivity were found in a number of areas, including left inferior parietal lobe and left hippocampus proper. The reactivity of posterior cingulate and hippocampal structures to cholinergic challenge suggests a key role of the cholinergic system in the functional processes that lead to Alzheimer's disease. The differential response to cholinergic challenge in mild cognitive impairment and Alzheimer patients may reflect a difference in the functional status of the cholinergic system between both groups, which is in line with recent results showing a differential clinical response to cholinergic treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Greicius, M. D., Srivastava, G., Reiss, A. L., & Menon, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308627101 · Cited by 3,684 · cited 2×
“…fMRI shows that resting state hypometabolism or hypofunction in limbic areas is central to pathology in both very early Alzheimer's disease (i.e. mild cognitive impairment ) and mild-to-moderate Alzheimer's disease (Matsuda, 2001; Nestor et al., 2003; Greicius et al., 2004; Rombouts et al., 2005).”
BackgroundImaging Cognition II: An Empirical Review of 275 PET and fMRI Studies
Cabeza, R., & Nyberg, L. (2000) · Journal of Cognitive Neuroscience · doi:10.1162/08989290051137585 · Cited by 3,598
Forman, S. D., Cohen, J. D., Fitzgerald, M., Eddy, W. F., Mintun, M. A., & Noll, D. C. (1995) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910330508 · Cited by 3,202 · cited 1×
“This was done for all regime types in both patient groups in a mixed effects higher level analysis (Woolrich et al., 2004), using clusters determined by Z > 2.3 and a corrected cluster significance threshold of P = 0.05 (Worsley et al., 1992; Friston et al., 1994; Forman et al., 1995).”
MethodInfluentialThe organization of recent and remote memories
Frankland, P. W., & Bontempi, B. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1607 · Cited by 2,138
A three-dimensional statistical analysis for CBF activation studies in human brain
Worsley, K. J., Evans, A. C., Marrett, S., & Neelin, P. (1992) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1992.127 · Cited by 2,036
Assessing the significance of focal activations using their spatial extent
Friston, K. J., Worsley, K. J., Frackowiak, R. S. J., Mazziotta, J. C., & Evans, A. C. (1994) · Human Brain Mapping · doi:10.1002/hbm.460010306 · Cited by 1,907 · cited 1×
“This was done for all regime types in both patient groups in a mixed effects higher level analysis (Woolrich et al., 2004), using clusters determined by Z > 2.3 and a corrected cluster significance threshold of P = 0.05 (Worsley et al., 1992; Friston et al., 1994; Forman et al., 1995).”
MethodInfluentialMorris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
Prefrontal and medial temporal lobe interactions in long-term memory
Simons, J. S., & Spiers, H. J. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1178 · Cited by 961
Bartus, R. T. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7397 · Cited by 829
Cited by
The cholinergic system in aging and neuronal degeneration
Schliebs, R., & Arendt, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.058 · Cited by 1,047
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Hampel, H., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 631
The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease
Schliebs, R., & Arendt, T. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0579-2 · Cited by 530
Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease
Richter, N., Beckers, N., Onur, O. A., Dietlein, M., Tittgemeyer, M., Kracht, L., Neumaier, B., Fink, G. R., & Kukolja, J. (2018) · Brain · doi:10.1093/brain/awx356 · Cited by 77
“This negative outcome of meta-analyses is surprising in light of basic research indicating a positive effect of AChE inhibitors on memory-related brain activation in MCI and even cogni- tively normal older individuals (Goekoop et al., 2006; Grön et al., 2006; Kukolja et al., 2009; Pa et al., 2013).”
ResultCognitive go/No-go decision-making criteria in Alzheimer’s disease drug development
Wessels, A. M., Edgar, C. J., Nathan, P. J., Siemers, E. R., Maruff, P., & Harrison, J. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.012 · Cited by 7
Metadata
- Authors
- Goekoop, R., Scheltens, P., Barkhof, F., & Rombouts, S. A. R. B.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-10-26
- Volume
- 129
- Issue
- 1
- Pages
- 141-157
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2058162427
- Cited by
- 116
- References
- 18
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation—a pharmacological fMRI study. https://app.cochat.ai/papers/10.1093/brain/awh671
- The paper
- Goekoop, R., Scheltens, P., Barkhof, F., & Rombouts, S. A. R. B. (2006). Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation—a pharmacological fMRI study. Brain. https://doi.org/10.1093/brain/awh671
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.